Trans-Atlantic pairing unite on MAbs research

14 January 2025

UK medical research charity LifeArc and US non-profit, multispecialty academic medical center Cleveland Clinic have signed a new 10-year master services agreement (MSA) for the development of monoclonal antibody-based therapeutics.

LifeArc will provide expertise in humanization of monoclonal antibodies (MAbs) to target key drivers of conditions identified by Cleveland Clinic, including cancer and complement-mediated diseases.

This MSA builds on a successful track record of the two organizations working together since 2019 on four humanization projects, with a fifth project for 2025 already underway. 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology